POZEN, Inc. (NASDAQ:POZN)
| CAPS Rating |
|
|---|---|
| Open | $4.51 |
| Previous Close | $4.57 |
| Daily Range | $4.41 - $4.53 |
| 52-Week Range | $2.15 - $6.39 |
| Market Cap | $132.23M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 50,085 |
| Average Daily Volume | 0 |
POZN
VS S&P 500 (SPY)
How do you think POZN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
POZN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
POZN News and Commentary
- 5 of Last Week's Biggest Winners – The Motley Fool
- Pozen Inks $75 Million Royalty Deal for Treximet – The Motley Fool
- Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry? – The Motley Fool
- 7 Must See Trade Setups For Today – Blog at The Motley Fool
- Acadia Pharmaceuticals: Investing With No Safety Net – Minyanville
- Acadia Pharmaceuticals - Investing With No Safety Net – Blog at The Motley Fool
- Pozen Continues Fighting Off Dr. Reddy's Labs – SeekingAlpha
- Pozen, AstraZeneca Sue Dr Reddy's Over Vimovo Generic – SmartMoney
- Pozen Wins Injunction Blocking Generic Migraine Drug – The Motley Fool
- Pozen: Injunction Stops Par From Selling Generic Of Pozen Drug – SmartMoney
- FDA Insider Trading: Time for an Overhaul? – SeekingAlpha
- Throw the Book at This Guy – The Motley Fool
- Pozen's Success Will Depend on Execution of Unique Marketing Strategies – SeekingAlpha
- What's Pozen Really Worth? – SeekingAlpha
- Youth in Revolt Against POZEN – The Motley Fool
- Maximizing Opportunity and Minimizing Risk With Trading FDA Decisions – SeekingAlpha
- Cadence: Patient Investors Should Watch Short Sellers Before FDA Decision on Thursday – SeekingAlpha
- Pozen CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha
- Pozen CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- AstraZeneca Has European Backing For Arthritis Pain Pill – SmartMoney
RSS Headlines
Fool UK
